Precigen Past Earnings Performance

Past criteria checks 0/6

Precigen has been growing earnings at an average annual rate of 16%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 52% per year.

Key information

16.0%

Earnings growth rate

28.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-52.0%
Return on equity-252.0%
Net Margin-3,521.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Feb 28
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 20

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Nov 04
Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Jul 18
Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

May 15
Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18
Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10
Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10
Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Revenue & Expenses Breakdown

How Precigen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PGEN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244-140416
30 Jun 244-135400
31 Mar 245-97390
31 Dec 236-96400
30 Sep 237-854236
30 Jun 2322-73430
31 Mar 2323-79460
31 Dec 2227-80480
30 Sep 2229-84480
30 Jun 2215-103490
31 Mar 2216-108510
31 Dec 2114-111520
30 Sep 2130-124710
30 Jun 2150-125820
31 Mar 2177-110850
31 Dec 2032-104730
30 Sep 20101-100880
30 Jun 2096-122880
31 Mar 2098-138890
31 Dec 1991-169990
30 Sep 19108-373850
30 Jun 19122-3811020
31 Mar 19134-4141170
31 Dec 18151-3751250
30 Sep 18194-1961480
30 Jun 18208-1791480
31 Mar 18217-1321530
31 Dec 17219-711300
30 Sep 17200-1341480
30 Jun 17203-1231430
31 Mar 17201-1541340
31 Dec 16191-1871380
30 Sep 16186-1751370
30 Jun 16191-1841250
31 Mar 16183-1761180
31 Dec 15174-841070
30 Sep 15163-33920
30 Jun 15131-47850
31 Mar 1598-59760
31 Dec 1472-82630
30 Sep 1448-113530
30 Jun 1433-52460
31 Mar 1428-11390
31 Dec 1324-57330

Quality Earnings: PGEN is currently unprofitable.

Growing Profit Margin: PGEN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.

Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: PGEN has a negative Return on Equity (-252.03%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies